ELRIG Flow Cytometry, Stevenage, UK
November 14, 2018
The high acquisition speed of modern flow cytometry instrumentation has made the technology a new asset in the high throughput drug discovery portfolio [1,2,3]. The multiplexed readouts support a broad range of critical research applications requiring quantification of cell surface and/or intracellular markers, allowing high-throughput flow cytometry to become a routinely applied technology along the complete discovery process, from phenotypic library screens to lead optimization. However, a data analysis solution suited for the unique requirements of high-throughput screening has so far been missing.
Here we discuss how Genedata Screener® can accelerate the efficiency of flow cytometry data analysis in both small molecule and antibody screening experiments. Genedata Screener combines flow-specific analyses and interactive views with powerful automated data processing and quality control. Fully integrated with the informatics landscape, it enables e.g. automated reporting to corporate warehouses and enterprise access to results and underlying data. The solution fits high throughput flow cytometry seamlessly into established screening workflows and infrastructure, directly funneling results to support compound progression decisions.
(1) Ding M et al., "Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective", SLAS Discovery, Vol.23(7) 719-731, 2018;
(2) Chan et al., “Flow Cytometry-Based Epitope Binning Using Competitive Binding Profiles for the Characterization of Monoclonal Antibodies against Cellular and Soluble Targets”, SLAS Discovery, Vol.23(7) 719-731, 2018;
(3) Wilson et al., “A Scalable Pipeline for High-Throughput Flow Cytometry”, Vol.23(7) 708-718, 2018